LFSC Price Forecast & ETF Analysis. Dividend · Expense Ratio · Holdings · NAV · RSI · MACD | US Stocks Today
AI-drawn chart patterns are for reference only.
Full metrics table
| Category | US Equities - Industry Sector | Expense | 0.54% | Return% 1Y | 31.1% | Total Holdings | 39 | Perf Week | -7.4% | Volume | 2,827 |
| Asset Type | Equities (Stocks) | AUM | $121M | Return% 3Y | - | NAV | $43.74 | Perf Month | 5.69% | Avg Volume | 0.00M |
| ETF Type | US Equities | Dividend TTM | - | Return% 5Y | - | 52W High | -11.36% | Perf Quarter | -10.73% | Rel Volume | 0.67 |
| Active/Passive | Active | Div Gr. 3/5Y | - | Return% 10Y | - | 52W Low | 31.67% | Perf Half Y | 18.65% | Prev Close | $43.69 |
| IPO | 2024/10/31 | Flows% 1M | -0.69% | Return% SI | 31.69% | RSI (14) | 46.06 | Perf YTD | 18.09% | Price | $43.24 |
| Beta | 0.95 | Flows% 3M | 0.48% | Flows% YTD | 8.13% | Flows% 1Y | 13.61% | Perf Year | 27.2% | Volatility(W/M) | 1.58% 1.75% |
| SMA20 | -2.06% | SMA50 | -1.39% | SMA200 | 5.17% | ATR | 1.08 | ||||
F/m Emerald Life Sciences Innovation ETF seeks long-term capital appreciation. The fund is an actively managed exchange-traded fund ("ETF") and invests primarily in equity securities of life science companies selected by Emerald Mutual Fund Advisers Trust, the fund's investment sub-adviser, under the supervision of the adviser. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities issued by life science companies demonstrating innovation.
The top 10 make up 54% of the fund
Largest sectors first.
Over the past 1 year, roughly in the middle
11% below its 1-year high.
Traded less than usual. That is 67% of its average volume.
Holding long would have paid off
Tap to view numbers
The price swings a lot
At its worst (November 2024) it fell 30% and took 136 days to recover.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Money keeps flowing in
Over the past year, new money equal to 13.6% of assets came in.
Tap to view numbers